Shanghai CureGene Pharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has announced the successful completion of a Series B financing round, raising RMB 100 million (USD 14 million). The financing was led by Tailong Capital, with additional investments from Elikon Venture and TigerYeah Capital, as well as participation from existing investors Vast Ocean Investment and Hankang Capital. The funds will be directed towards the clinical advancement of CureGene Pharma’s core cardiovascular product, CG-0255, and the progression of other pipeline products into clinical stages.
Established in 2018, CureGene Pharma is equipped with a world-leading targeted drug technology platform and a nucleic acid drug technology platform. CG-0255, a P2Y12 receptor antagonist, is being developed to address conditions such as acute coronary syndrome, myocardial infarction, and stroke, highlighting the company’s commitment to tackling significant cardiovascular diseases.- Flcube.com
